More than a decade of running had taken its toll on Katie Bodenstedt’s right knee.
Bodenstedt, 17, runs cross country and track for St. Ursula Academy in Toledo, but wasn’t able to compete this year because of her knee problems. She’s endured cortisone injections, arthroscopic surgery and two years of physical therapy. None of it seemed to work.
“I’d been running cross country since kindergarten, so it was a long time coming,” she says. “I went from running 5K races to not being able to run a mile.”
But she’s planning to compete next season, thanks to a treatment that puts her own blood to work for her.
In platelet-rich plasma therapy, blood is first taken from the patient and spun in a centrifuge. The process separates out plasma that’s rich with platelets containing proteins known as growth factors, which promote cell growth. These platelets are injected into the site of the injury. Most conditions require from one to three injections, although more are sometimes needed.
The treatment works for a variety of conditions involving tendons and ligaments, such as tennis elbow, plantar fasciitis, small rotator cuff tears, Achilles tendinitis, golfer’s elbow and patellar tendinitis, commonly known as jumper’s knee, according to Ronda Winans, a physical therapist and the director of sports care for the ProMedica Health System.
Using platelet-rich plasma therapy for these kinds of conditions is fairly new, which is why some research seems to indicate mixed results for the procedure, Winans says.
“There hasn’t been enough long-term research to validate it,” she says, “but what we see clinically is that it’s benefiting the patients.”
In fact, patients can often see the results themselves, since ultrasound is typically used to guide the injections. “They can see the ugly-looking tissue, and then down the road they can see the change,” Winans says.
Led by Dr. Roger Kruse, who practices with the Sports Care and Wildwood Family Practice in Toledo, ProMedica has been offering the treatment for about a year.
His success rate with the treatment is about 80 percent, Kruse says, but it’s not for everyone.
“You have to choose the right patients for it,” he says. “It’s not for every injury, and I think that’s why they get mixed reports, because they use it on the wrong medical problems.”
The best patients, he says, are those who want to avoid surgery and have conditions involving tendon or ligament soft tissue that have not responded to other treatments.